SARS-CoV-2 Seroprevalence among Health Care Workers-A Voluntary Screening Study in a Regional Medical Center in Southern Germany.
COVID-19
SARS-CoV-2
health care personnel
seroprevalence
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
08 04 2021
08 04 2021
Historique:
received:
04
03
2021
revised:
30
03
2021
accepted:
07
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
6
5
2021
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is associated with a potentially severe clinical manifestation, coronavirus disease 2019 (COVID-19), and currently poses a worldwide challenge. Health care workers (HCWs) are at the forefront of any health care system and thus especially at risk for SARS-CoV-2 infection due to their potentially frequent and close contact with patients suffering from COVID-19. Serum samples from 198 HCWs with direct patient contact of a regional medical center and several outpatient facilities were collected during the early phase of the pandemic (April 2020) and tested for SARS-CoV-2-specific antibodies. Commercially available IgA- and IgG-specific ELISAs were used as screening technique, followed by an in-house neutralization assay for confirmation. Neutralizing SARS-CoV-2-specific antibodies were detected in seven of 198 (3.5%) tested HCWs. There was no significant difference in seroprevalence between the regional medical center (3.4%) and the outpatient institution (5%). The overall seroprevalence of neutralizing SARS-CoV-2-specific antibodies in HCWs in both a large regional medical center and a small outpatient institution was low (3.5%) at the beginning of April 2020. The findings may indicate that the timely implemented preventive measures (strict hygiene protocols, personal protective equipment) were effective to protect from transmission of an airborne virus when only limited information on the pathogen was available.
Identifiants
pubmed: 33917840
pii: ijerph18083910
doi: 10.3390/ijerph18083910
pmc: PMC8068211
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nat Commun. 2020 Oct 8;11(1):5064
pubmed: 33033249
Euro Surveill. 2020 Apr;25(16):
pubmed: 32347204
JAMA. 2020 Jun 9;323(22):2245-2246
pubmed: 32391855
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
Ann Epidemiol. 2020 Aug;48:23-29.e4
pubmed: 32648546
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
Nat Commun. 2020 Nov 17;11(1):5829
pubmed: 33203887
MMWR Morb Mortal Wkly Rep. 2020 Sep 04;69(35):1221-1226
pubmed: 32881855
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Emerg Infect Dis. 2020 Jul;26(7):1470-1477
pubmed: 32255761
J Pathol. 2006 Jan;208(2):270-82
pubmed: 16362985
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Lancet Infect Dis. 2020 Dec;20(12):1401-1408
pubmed: 32758438
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Euro Surveill. 2020 May;25(18):
pubmed: 32400364
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
Immunity. 2020 Jul 14;53(1):98-105.e5
pubmed: 32561270
N Engl J Med. 2020 May 14;382(20):1957-1958
pubmed: 32243118